Interim Phase 2a Data: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities
Hoth Therapeutics, Inc.’s HT-001 showed promising interim safety and efficacy results from its Phase 2a clinical trial addressing skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients. HT-001 topical gel is anticipated to inhibit recruitment and activation of immune cells, reducing inflammation. Fully 100% of patients in Cohort 1 achieved the primary efficacy […]